Targeted oncolytic herpes simplex virus type 1 eradicates experimental pancreatic tumors

Human Gene Therapy

Volumn 26, Issue 2, 2015, Pages 104-113

  Gayral, Marion ^a   Lulka, Hubert ^a   Hanoun, Naima ^a   Biollay, Coline ^b   Sèlves, Janick ^a,c   Vignolle Vidoni, Alix ^a   Berthommé, Hervé ^b   Trempat, Pascal ^b   Epstein, Alberto L ^d   Buscail, Louis ^a,c   Béjot, Jean Luc ^e   Cordelier, Pierre ^a  

^a CANCER RESEARCH CENTER OF TOULOUSE   (France)

^b Bioviron   (France)

^c CHU RANGUEIL   (France)

^d LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^e Karcinolys   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GEMCITABINE; ONCOLYTIC HERPES VIRUS; PROTEIN MYB; ANTINEOPLASTIC AGENT; CELL CYCLE PROTEIN; DEOXYCYTIDINE; HERPES SIMPLEX VIRUS TYPE 1-PROTEIN ICP6; MYBL2 PROTEIN, HUMAN; TRANSACTIVATOR PROTEIN; VIRAL PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL LINE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; CYTOTOXICITY ASSAY; GENE EXPRESSION; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CELL; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; PANCREAS ADENOCARCINOMA; TUMOR GROWTH; TUMOR NECROSIS; VIRUS MUTATION; VIRUS REPLICATION; ANALOGS AND DERIVATIVES; ANIMAL; CANCER TRANSPLANTATION; CARCINOMA, PANCREATIC DUCTAL; DISEASE MODEL; GENE EXPRESSION REGULATION; GENETIC ENGINEERING; GENETICS; INTRALESIONAL DRUG ADMINISTRATION; METABOLISM; NUDE MOUSE; PANCREAS; PANCREATIC NEOPLASMS; PATHOLOGY; PROCEDURES; PROMOTER REGION; TUMOR CELL LINE; TUMOR VOLUME; VIROLOGY;

HUMAN HERPESVIRUS 1; MUS;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, PANCREATIC DUCTAL; CELL CYCLE PROTEINS; CELL LINE, TUMOR; DEOXYCYTIDINE; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; GENETIC ENGINEERING; HERPESVIRUS 1, HUMAN; HUMANS; INJECTIONS, INTRALESIONAL; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; ONCOLYTIC VIROTHERAPY; PANCREAS; PANCREATIC NEOPLASMS; PROMOTER REGIONS, GENETIC; TRANS-ACTIVATORS; TUMOR BURDEN; VIRAL PROTEINS;

EID: 84923118521     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2014.072     Document Type: Article

References (29)

1. Siegel R, Naishadham D, and Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30.
2. Burris HA, 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403-2413.
3. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:1960-1966.
4. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011;364:1817-1825.
5. Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013;369:1691-1703.
6. Ilkow CS, Swift SL, Bell JC, et al. From scourge to cure: tumour-selective viral pathogenesis as a new strategy against cancer. PLoS Pathog 2014;10:e1003836.
7. Jones S, Hruban RH, Kamiyama M, et al. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science 2009;324:217.
8. Yachida S, Jones S, Bozic I, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 2010;467:1114-1126.
9. Touchefeu Y, Harrington K, Galmiche J, et al. Review article: gene therapy, recent developments and future prospects in gastrointestinal oncology. Aliment Pharmacol Ther 2010;32:953-968.
10. Wennier S, Li S, and McFadden G. Oncolytic virotherapy for pancreatic cancer. Expert Rev Mol Med 2011;13:e18.
11. Xu C, Li H, Su C, et al. Viral therapy for pancreatic cancer: tackle the bad guys with poison. Cancer Lett 2013; 333:1-8.
12. Gammon DB, Gowrishankar B, Duraffour S, et al. Vaccinia virus-encoded ribonucleotide reductase subunits are differentially required for replication and pathogenesis. PLoS Pathog 2010;6:e1000984.
13. Elford HL, Freese M, Passamani E, et al. Ribonucleotide reductase and cell proliferation. I. Variations of ribonucleotide reductase activity with tumor growth rate in a series of rat hepatomas. J Biol Chem 1970;245:5228-5233.
14. Mundschau LJ, and Faller DV. Endogenous inhibitors of the dsRNA-dependent eIF-2 alpha protein kinase PKR in normal and ras-transformed cells. Biochimie 1994;76:792-800.
15. Nakamura H, Kasuya H, Mullen JT, et al. Regulation of herpes simplex virus gamma(1)34.5 expression and oncolysis of diffuse liver metastases by Myb34.5. J Clin Invest 2002;109:871-882.
16. Chung RY, Saeki Y, and Chiocca EA. B-myb promoter retargeting of herpes simplex virus gamma34.5 gene-mediated virulence toward tumor and cycling cells. J Virol 1999;73: 7556-7564.
17. Eisenberg DP, Adusumilli PS, Hendershott KJ, et al. 5- fluorouracil and gemcitabine potentiate the efficacy of oncolytic herpes viral gene therapy in the treatment of pancreatic cancer. J Gastrointest Surg 2005;9:1068-1077; discussion 1077-1079.
18. Sicard F, Gayral M, Lulka H, et al. Targeting miR-21 for the therapy of pancreatic cancer. Mol Ther 2013;21:986-994.
19. Delpu Y, Lulka H, Sicard F, et al. The rescue of miR-148a expression in pancreatic cancer: an inappropriate therapeutic tool. PLoS One 2013;8:e55513.
20. Bournet B, Pointreau A, Souque A, et al. Gene expression signature of advanced pancreatic ductal adenocarcinoma using low density array on endoscopic ultrasound-guided fine needle aspiration samples. Pancreatology 2012;12:27-34.
21. Passer BJ, Cheema T, Zhou B, et al. Identification of the ENT1 antagonists dipyridamole and dilazep as amplifiers of oncolytic herpes simplex virus-1 replication. Cancer Res 2010;70:3890-3895.
22. Maréchal R, Bachet J-B, Mackey JR, et al. Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma. Gastroenterology 2012;143: 664-674.e1-6.
23. Nakagawa N, Murakami Y, Uemura K, et al. Combined analysis of intratumoral human equilibrative nucleoside transporter 1 (hENT1) and ribonucleotide reductase regulatory subunit M1 (RRM1) expression is a powerful predictor of survival in patients with pancreatic carcinoma treated with adjuvant gemcitabine-based chemotherapy after operative resection. Surgery 2013;153:565-575.
24. Poplin E, Wasan H, Rolfe L, et al. Randomized, multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma: including a prospective evaluation of the role of hENT1 in gemcitabine or CO-101 sensitivity. J Clin Oncol 2013;31: 4453-4461.
25. Jones S, Zhang XS, Parsons DW, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008;321:1801-1806.
26. Russell SJ, Peng K-W, and Bell JC. Oncolytic virotherapy. Nat Biotechnol 2012;30:658-670.
27. Chou J, Kern ER, Whitley RJ, et al. Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth in culture. Science 1990;250:1262-1266.
28. Rebours V, Albuquerque M, Sauvanet A, et al. Hypoxia pathways and cellular stress activate pancreatic stellate cells: development of an organotypic culture model of thick slices of normal human pancreas. PLoS One 2013;8: e76229.
29. Kulu Y, Kawasaki H, Donahue JM, et al. Concurrent chemotherapy inhibits herpes simplex virus-1 replication and oncolysis. Cancer Gene Ther 2013;20:133-140.